Cullinan Oncology rises on FDA's nod for cancer drug trial in humans
24/01/2023 14:02
** Shares of cancer-focused biopharma co Cullinan Oncology
CGEM.O rise 7.4% to $11.25 premarket
** The U.S. Food and Drug Administration gives its go-ahead
for the company to begin human trials on its antibody agent,
CLN-978, which is a potential treatment for a type of lymphatic
cancer
** CGEM plans to initially test CLN-978 in a dose-escalation
study to evaluate the drug's safety and efficacy
** Co also plans to seek trial permission for CLN-617, co's
investigational protein used to treat tumors, in H1 2023
** Stock has declined 15% in last 12 months
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))